Published Date: 08 Mar 2023
Plant-based vegetarian and vegan diets may have the lowest carbon footprint in the United States, but new data analysis shows fish-based pescatarian diets are the best.
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
automated, precise reporting for clonality testing using NGS.
4.
Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC
5.
Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities
1.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
2.
Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights
3.
Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts
4.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Thromboprophylaxis In Medical Settings
4.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation